Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

Mult Scler. 1996 Jul;1(6):348. doi: 10.1177/135245859600100613.

Authors

O Andersen¹, J Lycke, P O Tollesson, A Svenningsson, B Runmarker, A S Linde, M Aström, P Gjörstrup, S Ekholm

Affiliation

¹ Department of Clinical Neuroscience, University of Götenborg, Sweden.

PMID: 9345415
DOI: 10.1177/135245859600100613

No abstract available

Publication types

Clinical Trial
Controlled Clinical Trial
Randomized Controlled Trial

MeSH terms

Adjuvants, Immunologic / therapeutic use*
Double-Blind Method
Humans
Hydroxyquinolines / therapeutic use*
Multiple Sclerosis / drug therapy*
Recurrence
Remission Induction
Treatment Outcome

Substances

Adjuvants, Immunologic
Hydroxyquinolines
roquinimex